LUMIGAN Drug Patent Profile
✉ Email this page to a colleague
When do Lumigan patents expire, and what generic alternatives are available?
Lumigan is a drug marketed by Abbvie and is included in two NDAs. There are twelve patents protecting this drug and two Paragraph IV challenges.
This drug has thirty-four patent family members in twenty-two countries.
The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lumigan
A generic version of LUMIGAN was approved as bimatoprost by APOTEX on December 1st, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUMIGAN?
- What are the global sales for LUMIGAN?
- What is Average Wholesale Price for LUMIGAN?
Summary for LUMIGAN
| International Patents: | 34 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 46 |
| Patent Applications: | 4,457 |
| Drug Prices: | Drug price information for LUMIGAN |
| Drug Sales Revenues: | Drug sales revenues for LUMIGAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LUMIGAN |
| What excipients (inactive ingredients) are in LUMIGAN? | LUMIGAN excipients list |
| DailyMed Link: | LUMIGAN at DailyMed |
Recent Clinical Trials for LUMIGAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Laboratoires Thea | Phase 1 |
| Amneal Pharmaceuticals, LLC | Phase 3 |
| Mankind Pharma Limited | Phase 3 |
Pharmacology for LUMIGAN
| Drug Class | Prostaglandin Analog |
Paragraph IV (Patent) Challenges for LUMIGAN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LUMIGAN | Ophthalmic Solution | bimatoprost | 0.01% | 022184 | 1 | 2011-04-05 |
| LUMIGAN | Ophthalmic Solution | bimatoprost | 0.03% | 021275 | 1 | 2008-12-22 |
US Patents and Regulatory Information for LUMIGAN
LUMIGAN is protected by thirteen US patents.
Patents protecting LUMIGAN
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING GLAUCOMA IN A PATIENT
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF LOWERING INTRAOCULAR PRESSURE
Enhanced bimatoprost ophthalmic solution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LUMIGAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 021275-001 | Mar 16, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | LUMIGAN | bimatoprost | SOLUTION/DROPS;OPHTHALMIC | 022184-001 | Aug 31, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for LUMIGAN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| AbbVie Deutschland GmbH & Co. KG | Lumigan | bimatoprost | EMEA/H/C/000391 Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., |
Authorised | no | no | no | 2002-03-08 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for LUMIGAN
See the table below for patents covering LUMIGAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 1753434 | SOLUTION OPHTALMIQUE DE BIMATOPROST AMELIOREE (ENHANCED BIMATOPROST OPHTHALMIC SOLUTION) | ⤷ Sign Up |
| Brazil | PI0607447 | solução oftálmica de bimatoprost aprimorada | ⤷ Sign Up |
| Norway | 20074390 | ⤷ Sign Up | |
| Germany | 10299037 | ⤷ Sign Up | |
| Russian Federation | 2007133919 | УЛУЧШЕННЫЙ ОФТАЛЬМИЧЕСКИЙ РАСТВОР БИМАТОПРОСТА | ⤷ Sign Up |
| Japan | 5563515 | ⤷ Sign Up | |
| South Korea | 101177598 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMIGAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | SPC023/2002 | Ireland | ⤷ Sign Up | SPC023/2002: 20040929, EXPIRES: 20170307 |
| 0660716 | 02C0033 | France | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| 0660716 | SPC/GB02/035 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | 90957 | Luxembourg | ⤷ Sign Up | |
| 0660716 | CA 2002 00020 | Denmark | ⤷ Sign Up | |
| 0660716 | C300099 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
